Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerThe combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyChanges in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling.Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ.Osteopontin splice variants are differential predictors of breast cancer treatment responsesOsteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer PatientsGenetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.Breast cancer as a systemic disease: a view of metastasisAssessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.RAN GTPase and Osteopontin in Pancreatic Cancer.An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.Role of osteopontin in the pathophysiology of cancer.Osteopontin as a therapeutic target for cancer.The functional interplay between systemic cancer and the hematopoietic stem cell niche.Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.The role of osteopontin expression in melanoma progression.Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.Fibroblasts play a potential role in bone destruction via osteopontin related caldesmon expression and polymerization in human non-functioning pituitary adenomas.Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling.
P2860
Q26766638-B0DA74AE-4FE3-4CF0-ADA6-994478363DD1Q26778586-856FAFAB-5FD4-452D-BB1F-534EB12F1418Q28388750-E98968DD-5406-411D-9ADE-8F3C3574B90CQ33823827-6D9A5497-0714-4122-9D8B-D9D714BFC2E4Q35167752-F1395F5B-AB42-4A38-83A6-C92B4E46DD8FQ35664216-A667539B-074D-4F3D-A7AF-5F19E2382F22Q36072882-699A2326-5F71-4A35-AC35-029D2A5ABEAFQ36095801-46A67B6B-D0BC-4FF5-8586-70E636594446Q36782301-07ADD68E-72E7-4AFF-BDE7-5A8257C7E136Q37011741-278F9AD0-DAE0-4A61-B08C-75C5D17F7D6BQ37690307-F1D0FE09-D028-4FB3-BD0E-9AB561042A17Q37707966-47B49131-5CBB-4215-89EE-D6096F402F11Q38192714-AB1D83CA-5F49-4031-A99B-72D5D90F05EEQ38198463-0EE57206-2CD6-4DBC-8AE3-12FD8FD92000Q38217758-5D261BB1-5CCE-4715-9542-40A1B504E225Q38946667-4B0423D4-B247-40D8-9E58-F38519C8258DQ39977787-A9B21252-0647-4A2B-AF8F-069F5FF63494Q40112666-BA8A9285-6F33-401E-8A0B-735529694430Q40973252-3B147378-0453-4E69-BC98-E21013C176C3Q41338779-77B20E5B-6282-4EE4-8D1C-AD63FBBCCA6CQ47135561-3E314242-C30B-4195-B9DC-7122D56AF4DFQ47143392-D8AEF2A0-B33A-4AA9-AA8F-E41AC0CBC5CDQ51697993-7E3C0C91-0BF2-44A8-90B4-4DC043FF8064Q51734190-2A761B94-0146-4932-9C4F-0E7C840F24F5
P2860
Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Plasma osteopontin as a biomar ...... tegory and treatment response.
@ast
Plasma osteopontin as a biomar ...... tegory and treatment response.
@en
type
label
Plasma osteopontin as a biomar ...... tegory and treatment response.
@ast
Plasma osteopontin as a biomar ...... tegory and treatment response.
@en
prefLabel
Plasma osteopontin as a biomar ...... tegory and treatment response.
@ast
Plasma osteopontin as a biomar ...... tegory and treatment response.
@en
P2093
P2860
P50
P356
P1476
Plasma osteopontin as a biomar ...... ategory and treatment response
@en
P2093
E Christensen
K Chadwick
M Pintilie
N Fleshner
P H Anborgh
P2860
P2888
P304
P356
10.1038/BJC.2012.345
P407
P577
2012-08-07T00:00:00Z